Spots Global Cancer Trial Database for GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Official Title: GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Study ID: NCT02321592
Conditions
Interventions
Study Description
Brief Summary: The study is designed * to demonstrate efficacy of AFM13 with an optimized treatment schedule * to decide whether AFM13 warrants further investigation in a phase III clinical trial
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
1st Department of Medicine, Cologne University Hospital, Cologne, , Germany
Contact Details
Name: Andreas Engert, Prof.
Affiliation: University Hospital of Cologne
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
